Foghorn Therapeutics, Inc. (FHTX)

NASDAQ: FHTX · IEX Real-Time Price · USD
16.93 -0.68 (-3.86%)
Jan 18, 2022 2:15 PM EST - Market open
Market Cap695.70M
Revenue (ttm)857,000
Net Income (ttm)-92.94M
Shares Out41.09M
EPS (ttm)-2.69
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume145,082
Open17.24
Previous Close17.61
Day's Range16.80 - 18.28
52-Week Range8.01 - 25.10
Betan/a
AnalystsBuy
Price Target28.25 (+66.9%)
Earnings Daten/a

About FHTX

Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines targeting genetically determined dependencies within the chromatin regulatory system. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It is developing FHD-286, a small molecule inhibitor of the enzymatic activity of BRG1 and BRM for the treatment of metastatic uveal melanoma and relapsed and/or refractory acute myeloid leukemia; and FHD-609, a small molecule...

IndustryBiotechnology
IPO DateOct 23, 2020
Employees95
Stock ExchangeNASDAQ
Ticker SymbolFHTX
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 5 analysts, the average rating for FHTX stock is "Buy." The 12-month stock price forecast is 28.25, which is an increase of 66.86% from the latest price.

Price Target
$28.25
(66.86% upside)
Analyst Consensus: Buy

News

How Much Upside is Left in Foghorn Therapeutics Inc. (FHTX)? Wall Street Analysts Think 26%

The consensus price target hints at a 25.6% upside potential for Foghorn Therapeutics Inc. (FHTX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in ea...

6 days ago - Zacks Investment Research

Foghorn Therapeutics Inc. (FHTX) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now

Foghorn Therapeutics Inc. (FHTX) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions ...

1 week ago - Zacks Investment Research

Foghorn Therapeutics Announces Chief Scientific Officer Succession

CAMBRIDGE, Mass., Jan. 10, 2022 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a company pioneering the discovery and development of a new class of medicines targeting genetically determ...

1 week ago - GlobeNewsWire

Foghorn Therapeutics to Participate at the H.C. Wainwright BioConnect Conference

CAMBRIDGE, Mass., Jan. 07, 2022 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a company pioneering the discovery and development of a new class of medicines targeting genetically determ...

1 week ago - GlobeNewsWire

Why Foghorn Therapeutics Blasted 55% Higher Today

The clinical-stage biotech could reap as much as $1.3. billion from a new research and development pact with a heavy-hitting partner.

1 month ago - The Motley Fool

FHTX Stock Alert: 7 Things to Know About the Partnership Lifting Foghorn Today

Shares of FHTX stock are surging today after the company announced a partnership with Eli Lilly. Here's what you should know.

1 month ago - InvestorPlace

Foghorn Therapeutics Stock Surges After $1.5B Cancer Pact With Eli Lilly

Loxo Oncology, an R&D group of Eli Lilly And Co (NYSE: LLY), and Foghorn Therapeutics Inc (NASDAQ: FHTX) have collaborated to create oncology medicines by applying Foghorn's Gene Traffic Control platfor...

Other symbols:LLY
1 month ago - Benzinga

Lilly and Foghorn Announce Strategic Collaboration for Novel Oncology Targets Using Foghorn's Proprietary Gene Traffi...

INDIANAPOLIS and CAMBRIDGE, Mass. , Dec. 13, 2021 /PRNewswire/ -- Loxo Oncology at Lilly, a research and development group of Eli Lilly and Company (NYSE: LLY), and Foghorn Therapeutics Inc. (Nasdaq: FH...

Other symbols:LLY
1 month ago - PRNewsWire

Foghorn Therapeutics Provides Third Quarter 2021 Corporate Update

-- First patient dosed in phase 1 clinical trial of FHD-609, a potent and selective heterobifunctional protein degrader of BRD9, initially being developed for the treatment of synovial sarcoma

2 months ago - GlobeNewsWire

Foghorn Therapeutics Announces Presentation at Upcoming 4th Annual Targeted Protein Degradation Summit

David Millan, PhD, VP of Chemistry, to present overview of company's proprietary protein degrader platform and its clinical stage asset, FHD-609, a potent and selective heterobifunctional degrader of BR...

2 months ago - GlobeNewsWire

Foghorn Therapeutics to Participate in Two Upcoming Virtual Investor Conferences

CAMBRIDGE, Mass., Sept. 01, 2021 (GLOBE NEWSWIRE) -- Foghorn Therapeutics Inc. (Nasdaq: FHTX), a clinical stage biotechnology company pioneering a new class of medicines that modulate gene expression th...

4 months ago - GlobeNewsWire

Foghorn Therapeutics Announces First Patient Dosed in First-in-Human Clinical Trial of FHD-609

FHD-609 is a first-in-class, highly potent and selective protein degrader of BRD9

4 months ago - GlobeNewsWire

Foghorn Therapeutics Provides Second Quarter 2021 Corporate Update

-- First Patients Dosed in Phase 1 Clinical Trials of FHD-286, an Inhibitor of BRG1/BRM, in Metastatic Uveal Melanoma and Relapsed or Refractory Acute Myeloid Leukemia (AML)

5 months ago - GlobeNewsWire

Foghorn Therapeutics to Participate at the 2021 Wedbush PacGrow Healthcare Virtual Conference

CAMBRIDGE, Mass., Aug. 03, 2021 (GLOBE NEWSWIRE) -- Foghorn Therapeutics Inc. (Nasdaq: FHTX), a company pioneering the discovery and development of a new class of medicines targeting genetically determi...

5 months ago - GlobeNewsWire

Foghorn Therapeutics to Participate at the William Blair Biotech Focus Conference 2021

CAMBRIDGE, Mass., July 09, 2021 (GLOBE NEWSWIRE) -- Foghorn Therapeutics Inc. (Nasdaq: FHTX), a company pioneering the discovery and development of a new class of medicines targeting genetically determi...

6 months ago - GlobeNewsWire

Foghorn Therapeutics Appoints Ian Smith to its Board of Directors

CAMBRIDGE, Mass., April 28, 2021 (GLOBE NEWSWIRE) -- Foghorn Therapeutics Inc. (Nasdaq: FHTX), a company pioneering the discovery and development of a new class of medicines targeting genetically determ...

8 months ago - GlobeNewsWire

Is a Surprise Coming for Foghorn Therapeutics (FHTX) This Earnings Season?

Foghorn Therapeutics (FHTX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

9 months ago - Zacks Investment Research

UPDATE: Foghorn Therapeutics to Present Poster and Chair a Panel at the AACR Annual Meeting 2021

CAMBRIDGE, Mass., March 11, 2021 (GLOBE NEWSWIRE) -- Foghorn Therapeutics Inc. (Nasdaq: FHTX), a company pioneering the discovery and development of a new class of medicines targeting genetically determ...

10 months ago - GlobeNewsWire

Foghorn Therapeutics to Present Poster and Chair a Panel and at the AACR Annual Meeting 2021

CAMBRIDGE, Mass., March 11, 2021 (GLOBE NEWSWIRE) -- Foghorn Therapeutics Inc. (Nasdaq: FHTX), a company pioneering the discovery and development of a new class of medicines targeting genetically determ...

10 months ago - GlobeNewsWire

Cellarity Raises $123 Million in Series B Funding to Pioneer a New Approach to Drug Discovery, Treating Disease at th...

CAMBRIDGE, Mass., Feb. 25, 2021 /PRNewswire/ -- Cellarity, a life sciences company founded by Flagship Pioneering to develop a new method of drug discovery targeting the cell, announced today that it ra...

10 months ago - PRNewsWire

Foghorn Therapeutics to Participate in the 41st Cowen Annual Healthcare Conference

CAMBRIDGE, Mass., Feb. 22, 2021 (GLOBE NEWSWIRE) -- Foghorn Therapeutics Inc. (Nasdaq: FHTX), a company pioneering the discovery and development of a new class of medicines targeting genetically determi...

10 months ago - GlobeNewsWire

Foghorn Therapeutics Appoints Michael LaCascia as Chief Legal Officer

CAMBRIDGE, Mass., Nov. 12, 2020 (GLOBE NEWSWIRE) -- Foghorn Therapeutics Inc. (Nasdaq: FHTX), a company pioneering the discovery and development of a new class of medicines targeting genetically determi...

1 year ago - GlobeNewsWire

Foghorn Therapeutics Announces Pricing of Initial Public Offering

CAMBRIDGE, Mass., Oct. 22, 2020 (GLOBE NEWSWIRE) -- Foghorn Therapeutics Inc. (Nasdaq: FHTX), a company pioneering the discovery and development of a new class of medicines targeting genetically determi...

1 year ago - GlobeNewsWire

Foghorn Therapeutics sets IPO terms, to raise up to $127.5 million

Foghorn Therapeutics Inc. set terms for its initial public offering Monday, as the Massachusetts-based company focused on the chromatin regulatory system that leads to gene expression looks to raise up ...

1 year ago - Market Watch